VCM
INDV icon

Versant Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Versant Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.94K Buy
+54
New +$2.04K ﹤0.01% 2615

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Versant Capital Management's INDV Position: Q3 2026 in Review

Versant Capital Management opened a new position in Indivior Pharmaceuticals (INDV) in Q3 2026: 54 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #2615 among its holdings.

9 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • Versant Capital Management held 54 shares of Indivior Pharmaceuticals worth $1.94K as of Q3 2026.
  • Indivior Pharmaceuticals was a new Versant Capital Management position in Q3 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2615 holding.
  • 9 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.